High‐titre anti‐SARS‐CoV‐2 convalescent plasma donation after donors’ vaccination

Romón, Íñigo; Arroyo, José Luis; Díaz, Teresa Suárez; Dominguez-Garcia, Juan J; Briz, Montserrat

doi:10.1111/vox.13094

Cited by 5 publications

(6 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This flexible strategy for identifying dCCP with high antibody titers and activity can improve the therapeutic efficacy of dCCP for improved intervention as the epidemic evolves. Additionally, vaccine‐boosted dCCP with hybrid/uber‐antibodies might be promising to increase the neutralization efficacy of CCP 81–85 . Applying the novel characterizations of dCCP in the setting of early disease treatment, for example, in outpatient settings as shown by Sullivan et al 38 might optimize the effect of CCP transfusion.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, vaccine‐boosted dCCP with hybrid/uber‐antibodies might be promising to increase the neutralization efficacy of CCP. 81 , 82 , 83 , 84 , 85 Applying the novel characterizations of dCCP in the setting of early disease treatment, for example, in outpatient settings as shown by Sullivan et al 38 might optimize the effect of CCP transfusion. Resource‐limited settings with reduced access to expensive monoclonals and antiviral agents could also profit from such a flexible way of identification of high titer dCCP products.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Characterization of pathogen‐inactivated COVID‐19 convalescent plasma and responses in transfused patients

et al. 2022

View full text Add to dashboard Cite

Background: Efficacy of donated COVID-19 convalescent plasma (dCCP) is uncertain and may depend on antibody titers, neutralizing capacity, timing of administration, and patient characteristics.Study Design and Methods: In a single-center hypothesis-generating prospective case-control study with 1:2 matched dCCP recipients to controls according to disease severity at day 1, hospitalized adults with COVID-19 pneumonia received 2 Â 200 ml pathogen-reduced treated dCCP from 2 different donors. We evaluated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in COVID-19 convalescent plasma donors and recipients using multiple antibody assays including a Coronavirus antigen microarray (COVAM), and binding and neutralizing antibody assays. Outcomes were dCCP characteristics, antibody responses, 28-day mortality, and dCCP -related adverse events in recipients. Results: Eleven of 13 dCCPs (85%) contained neutralizing antibodies (nAb).PRT did not affect dCCP antibody activity. Fifteen CCP recipients and 30 controls (median age 64 and 65 years, respectively) were enrolled. dCCP recipients received 2 dCCPs from 2 different donors after a median of one hospital day and 11 days after symptom onset. One dCCP recipient (6.7%) and 6 controls (20%) died (p = 0.233). We observed no dCCP-related adverse events. Transfusion of unselected dCCP led to heterogeneous SARS CoV-2 antibody responses. COVAM clustered dCCPs in 4 distinct groups and showed endogenous immune responses to SARS-CoV-2 antigens over 14-21 days post dCCP in all except 4 immunosuppressed recipients. Discussion: PRT did not impact dCCP anti-virus neutralizing activity. Transfusion of unselected dCCP did not impact survival and had no adverse effects. Variable dCCP antibodies and post-transfusion antibody responses indicate the need for controlled trials using well-characterized dCCP with informative assays.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Characterization of pathogen‐inactivated COVID‐19 convalescent plasma and responses in transfused patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…An additional reason to reinitiate CCP collections is provided by the increased potential of the so‐called Vax‐CCP, that is, CCP harvested from patients who have been vaccinated after infection. Romon et al have shown that a single dose of mRNA vaccine in convalescents actually leads to Ortho Vitros® antibody levels predictive of high nAb content [13]. After two vaccine doses, Vax‐CCP can have extremely high nAb titres.…”

Section: Figurementioning

confidence: 99%

Are convalescent plasma stocks collected during former COVID‐19 waves still effective against current SARS‐CoV‐2 variants?

Focosi¹,

Franchini

Joyner

et al. 2022

Vox Sanguinis

View full text Add to dashboard Cite

COVID-19 convalescent plasma (CCP) was among the few frontline therapies used to treat COVID-19. After large randomized controlled trials (RCTs) relying on late use in hospitalized patients and/or low antibody titres failed to meet their predefined primary endpoint, the infectious disease community reduced usage of CCP in favour of monoclonal antibodies. Consequently, there are CCP stocks at most transfusion centres worldwide, although scattered usage continues. Further, better designed RCTs are also being launched. The urgent question here is: should we use CCP units collected months before given the largely changed viral variant landscape? We review here in vitro evidence that discourages usage of such CCP units against Delta and other variants of concern. CCP collections should be continued in order to update the armamentarium of therapeutics against vaccine breakthrough infections or in unvaccinated patients and is especially relevant in next-generation RCTs.

show abstract

“…Another study has shown that antibody responses to the first dose of mRNA vaccines (BNT162b2/Pfizer; mRNA-1273/Moderna) in individuals with pre-existing immunity from infection were equal to and frequently exceeded the titers found in naïve individuals after their second dose [95]. Thus, the collection of CovCP from vaccinated individuals who have recovered from primary infection is an area of interest [96]. Storage J o u r n a l P r e -p r o o f of plasma collected after vaccination could play a role in case of emergence of a more aggressive variant or during the existing vaccination gap in some countries and can be helpful to be better prepared for a next wave of infections.…”

Section: What Are the Lessons Learned For The Next Pandemic?mentioning

confidence: 99%

Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients

Beraud

Meyer

Lozano

et al. 2022

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Please cite this article as: { doi: https://doi.org/ This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

High‐titre anti‐SARS‐CoV‐2 convalescent plasma donation after donors’ vaccination

Cited by 5 publications

References 3 publications

Characterization of pathogen‐inactivated COVID‐19 convalescent plasma and responses in transfused patients

Characterization of pathogen‐inactivated COVID‐19 convalescent plasma and responses in transfused patients

Are convalescent plasma stocks collected during former COVID‐19 waves still effective against current SARS‐CoV‐2 variants?

Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients

Contact Info

Product

Resources

About